Koo

I just came up from the dock in Lake Muskoka. Hope you are enjoying your wine.

Good point regarding the value after the futility analysis and I sure hope you are right. Passing futility will IMHO certainly be another positive sign of the power of this science. However, I do not know what it will do to the demand for the stock and it's price. There is a long way to go after futility. If they continue to do DSMB reports and continue to pass it will help.

Hopefully it will focus some BP eyes and investor eyes and analysts eyes back on this stock. The post hoc learning from post ASSURE is extremely positive and the discovery of the multi-modal impacts of apabetalone has given RVX significant knowledge regarding the science.

Apabetalone is unique, oral and based on Don's charts seems to have the potential to be very cost effective and thus payers may be very interested. If it becomes one of  the standard of care drugs in ERs the take may be very fast and prolonged.

I'm headed back to the dock and the beer fridge.

GLTA

Toinv